Shawnte Mitchell Sells 25,000 Shares of Olema Pharmaceuticals (NASDAQ:OLMA) Stock

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) insider Shawnte Mitchell sold 25,000 shares of Olema Pharmaceuticals stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $24.25, for a total transaction of $606,250.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Shawnte Mitchell also recently made the following trade(s):

• On Tuesday, March 3rd, Shawnte Mitchell sold 15,000 shares of Olema Pharmaceuticals stock. The shares were sold at an average price of $23.01, for a total transaction of $345,150.00.

Olema Pharmaceuticals Stock Performance

NASDAQ:OLMA opened at $21.55 on Friday. The company’s 50-day moving average price is $25.16 and its 200-day moving average price is $18.06. The company has a current ratio of 8.03, a quick ratio of 8.03 and a debt-to-equity ratio of 0.01. The company has a market cap of $1.48 billion, a P/E ratio of -11.52 and a beta of 1.92. Olema Pharmaceuticals, Inc. has a twelve month low of $2.86 and a twelve month high of $36.26.

Analyst Ratings Changes

A number of research analysts have weighed in on OLMA shares. Piper Sandler initiated coverage on shares of Olema Pharmaceuticals in a research note on Wednesday, January 7th. They issued an “overweight” rating and a $40.00 target price on the stock. Citigroup lifted their price objective on Olema Pharmaceuticals from $21.00 to $60.00 and gave the stock a “buy” rating in a research report on Friday, December 12th. HC Wainwright upped their target price on Olema Pharmaceuticals from $36.00 to $45.00 and gave the company a “buy” rating in a report on Thursday, December 11th. The Goldman Sachs Group lifted their price target on Olema Pharmaceuticals from $26.00 to $38.00 and gave the stock a “buy” rating in a report on Thursday, December 11th. Finally, UBS Group initiated coverage on shares of Olema Pharmaceuticals in a research report on Wednesday, January 7th. They set a “buy” rating and a $45.00 price target on the stock. Nine research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Olema Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $41.78.

Institutional Trading of Olema Pharmaceuticals

Several institutional investors have recently made changes to their positions in OLMA. Siren L.L.C. purchased a new position in Olema Pharmaceuticals in the fourth quarter worth approximately $82,518,000. Janus Henderson Group PLC raised its position in Olema Pharmaceuticals by 87.1% in the fourth quarter. Janus Henderson Group PLC now owns 6,710,194 shares of the company’s stock valued at $167,901,000 after purchasing an additional 3,124,345 shares during the period. Cormorant Asset Management LP purchased a new stake in Olema Pharmaceuticals in the fourth quarter valued at $68,750,000. RA Capital Management L.P. acquired a new position in shares of Olema Pharmaceuticals in the 4th quarter valued at $65,000,000. Finally, Bain Capital Life Sciences Investors LLC lifted its stake in shares of Olema Pharmaceuticals by 24.3% in the 4th quarter. Bain Capital Life Sciences Investors LLC now owns 8,508,641 shares of the company’s stock valued at $212,716,000 after purchasing an additional 1,664,687 shares during the last quarter. Hedge funds and other institutional investors own 91.78% of the company’s stock.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.